JP2023541827A5 - - Google Patents
Info
- Publication number
- JP2023541827A5 JP2023541827A5 JP2023515289A JP2023515289A JP2023541827A5 JP 2023541827 A5 JP2023541827 A5 JP 2023541827A5 JP 2023515289 A JP2023515289 A JP 2023515289A JP 2023515289 A JP2023515289 A JP 2023515289A JP 2023541827 A5 JP2023541827 A5 JP 2023541827A5
- Authority
- JP
- Japan
- Prior art keywords
- copolymer
- pharmaceutical composition
- mol
- repeating units
- solid oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20194828 | 2020-09-07 | ||
| EP20194828.8 | 2020-09-07 | ||
| EP20208628 | 2020-11-19 | ||
| EP20208628.6 | 2020-11-19 | ||
| PCT/EP2021/074625 WO2022049310A1 (en) | 2020-09-07 | 2021-09-07 | Improved pharmaceutical formulations of glp-1 receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023541827A JP2023541827A (ja) | 2023-10-04 |
| JP2023541827A5 true JP2023541827A5 (enExample) | 2024-09-13 |
Family
ID=77821779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023515289A Pending JP2023541827A (ja) | 2020-09-07 | 2021-09-07 | Ｇｌｐ－１受容体アゴニストの改善された医薬製剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240041983A1 (enExample) |
| EP (1) | EP4210680A1 (enExample) |
| JP (1) | JP2023541827A (enExample) |
| CN (1) | CN116419750A (enExample) |
| WO (1) | WO2022049310A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| CA3237751A1 (en) | 2021-11-10 | 2023-05-19 | Tyler Brown | Ionic liquid compositions |
| WO2023166179A1 (en) * | 2022-03-03 | 2023-09-07 | Cyprumed Gmbh | Improved oral pharmaceutical formulations of therapeutic peptides and proteins |
| TW202400219A (zh) * | 2022-04-29 | 2024-01-01 | 香港商鵬躍醫藥科技有限公司 | 用於鼻內給藥的索馬魯肽及其鹽的藥物組合物 |
| KR20250057847A (ko) | 2022-08-29 | 2025-04-29 | 일라이 릴리 앤드 캄파니 | 경구 전달용 조성물 |
| WO2024134493A1 (en) * | 2022-12-19 | 2024-06-27 | Quisitive Therapeutics | Drug delivery system for tirzepatide |
| US12605427B2 (en) * | 2023-05-15 | 2026-04-21 | Red Mountain Med Spa, LLC | Sublingual semaglutide-BPC 157 combination for weight loss |
| CN122376711A (zh) * | 2024-06-03 | 2026-07-14 | 深圳奥礼生物科技有限公司 | 口服的多肽组合物 |
| WO2026084427A1 (ko) * | 2024-10-16 | 2026-04-23 | 국민대학교산학협력단 | 세마글루티드 및 흡수촉진제를 유효성분으로 포함하는 경구투여용 제제 및 이의 제조방법 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3219656A (en) | 1963-08-12 | 1965-11-23 | Rohm & Haas | Alkylpolyalkoxyalkyl glucosides and process of preparation therefor |
| US3839318A (en) | 1970-09-27 | 1974-10-01 | Rohm & Haas | Process for preparation of alkyl glucosides and alkyl oligosaccharides |
| AT382381B (de) | 1984-10-02 | 1987-02-25 | Oesterr Zuckerfab Evidenz | Verfahren zur herstellung neuer grenzfl|chenaktiver kohlenhydrat-derivate |
| DK39892D0 (da) | 1992-03-25 | 1992-03-25 | Bernard Thorens | Peptid |
| US5661130A (en) | 1993-06-24 | 1997-08-26 | The Uab Research Foundation | Absorption enhancers for drug administration |
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| US5866536A (en) | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| US5773647A (en) | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| DE69916811T2 (de) | 1998-02-27 | 2005-04-14 | Novo Nordisk A/S | Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden |
| EP1060191B1 (en) | 1998-02-27 | 2010-04-28 | Novo Nordisk A/S | Derivatives of glp-1 analogs |
| AU2610899A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | N-terminally modified glp-1 derivatives |
| AU3247799A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
| NZ534409A (en) | 1999-04-05 | 2006-03-31 | Emisphere Tech Inc | Disodium salts, monohydrates, and ethanol solvates for delivering active agents |
| EP1670515A2 (en) | 2003-09-19 | 2006-06-21 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| JP2007537141A (ja) | 2003-12-18 | 2007-12-20 | ノボ ノルディスク アクティーゼルスカブ | 新規なｇｌｐ−１化合物 |
| CN101665538A (zh) | 2003-12-18 | 2010-03-10 | 诺沃挪第克公司 | 与白蛋白样物质相连的新glp-1类似物 |
| ES2542228T3 (es) | 2004-07-08 | 2015-08-03 | Novo Nordisk A/S | Marcas de prolongación polipeptídica que comprenden un resto de tetrazol |
| US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| JP5107713B2 (ja) | 2004-10-07 | 2012-12-26 | ノヴォ ノルディスク アー／エス | 遅延性のエキセンディン−４化合物 |
| JP2008515856A (ja) | 2004-10-07 | 2008-05-15 | ノボ ノルディスク アクティーゼルスカブ | 遅延性ｇｌｐ−１化合物 |
| ES2484796T3 (es) | 2005-03-18 | 2014-08-12 | Novo Nordisk A/S | Compuestos de GLP-1 extendidos |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| US20090318353A1 (en) | 2006-08-25 | 2009-12-24 | Novo Nordisk A/S | Acylated Exendin-4 Compounds |
| US20100261637A1 (en) | 2007-09-05 | 2010-10-14 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| US20100292133A1 (en) | 2007-09-05 | 2010-11-18 | Novo Nordisk A/S | Truncated glp-1 derivaties and their therapeutical use |
| EP2190872B1 (en) | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| AU2010250452B2 (en) | 2009-05-20 | 2014-06-05 | Toray Industries, Inc. | Cell membrane-permeable peptides |
| CN102596253B (zh) | 2009-09-30 | 2013-11-06 | 蒂奥迈里克斯研究与指导有限公司 | 含有维生素b 亚结构的粘膜粘着聚合物 |
| KR20130100897A (ko) | 2010-04-21 | 2013-09-12 | 나노메가 메디컬 코포레이션 | 나노입자의 약제학적 조성물 |
| WO2012112319A1 (en) | 2011-02-04 | 2012-08-23 | Aegis Therapeutics, Llc | Orally bioavailable peptide drug compositions and methods thereof |
| CN103458873B (zh) | 2011-04-14 | 2016-04-13 | 诺沃—诺迪斯克有限公司 | 用于口服肽递送的脂肪酸酰化的氨基酸 |
| CN104080446B (zh) * | 2011-11-30 | 2018-06-29 | 武田药品工业株式会社 | 干包衣片 |
| CA2872314C (en) | 2012-05-03 | 2021-08-31 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| US20150174076A1 (en) | 2012-06-14 | 2015-06-25 | Entrega, Inc. | Mucoadhesive devices for delivery of active agents |
| WO2014060472A1 (en) * | 2012-10-17 | 2014-04-24 | Novo Nordisk A/S | Fatty acid acylated amino acids for oral peptide delivery |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| JP2017525656A (ja) | 2014-06-04 | 2017-09-07 | ノヴォ ノルディスク アー／エス | 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト |
| JP7211704B2 (ja) * | 2015-01-29 | 2023-01-24 | ノヴォ ノルディスク アー／エス | Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤 |
| CN105832691B (zh) * | 2016-05-31 | 2018-10-02 | 深圳市健元医药科技有限公司 | 一种度拉糖肽结肠定位缓释制剂及其制备方法 |
| WO2020160263A1 (en) * | 2019-01-30 | 2020-08-06 | Synlev Pharmaceuticals Corporation | Formulations and methods for treatment of fibromyalgia and related myofascial pain disorders |
-
2021
- 2021-09-07 WO PCT/EP2021/074625 patent/WO2022049310A1/en not_active Ceased
- 2021-09-07 EP EP21773092.8A patent/EP4210680A1/en active Pending
- 2021-09-07 US US18/043,976 patent/US20240041983A1/en active Pending
- 2021-09-07 JP JP2023515289A patent/JP2023541827A/ja active Pending
- 2021-09-07 CN CN202180075206.9A patent/CN116419750A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12396953B2 (en) | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid | |
| JP6356548B2 (ja) | エクセナチドの経口投与用の方法及び組成物 | |
| US20200030240A1 (en) | Sustained-release formulations of colchicine and methods of using same | |
| US20220370366A1 (en) | Tablets containing cilofexor and pharmaceutically acceptable carriers | |
| CN102292085A (zh) | 包含氨氯地平和氯沙坦的固体药物组合物及其制备方法 | |
| EP3730127A1 (en) | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid | |
| JP2011516613A (ja) | 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物 | |
| RU2013101767A (ru) | Новые дозированные формы с модифицированным высвобождением ингибитора ксантиноксидоредуктазы или ингибиторов ксантиноксидазы | |
| JP2022533368A5 (enExample) | ||
| CN108367001A (zh) | 治疗丁型肝炎病毒感染 | |
| JP2006515299A5 (enExample) | ||
| JP2019019112A (ja) | ４−［５−（ピリジン−４−イル）−１ｈ−１，２，４−トリアゾール−３−イル］ピリジン−２−カルボニトリル、又はその塩を含む徐放製剤。 | |
| US20120003274A1 (en) | Oral sustained release antidepressant formulation | |
| JPWO2014141847A1 (ja) | 骨系統疾患治療薬及びその用途 | |
| CA2620065A1 (en) | Methods and formulations for modulating lyn kinase activity and treating related disorders | |
| JP7355846B2 (ja) | 固形製剤 | |
| JP2025517683A5 (enExample) | ||
| JP2005528388A (ja) | 改善された制御放出調製物 | |
| US20210283096A1 (en) | Methods of treating obesity in responder and non-responder populations | |
| US20220257522A1 (en) | Dose dumping resistant pharmaceutical compositions comprising verinurad | |
| US20030220351A1 (en) | Enteric coated caffeine tablet | |
| US20250152527A1 (en) | Therapeutic combinations of colchicine and methods of using same | |
| Pathak et al. | Gastroretentive carrier systems in the delivery of therapeutic actives: an updated patent review | |
| US20260137642A1 (en) | Methods of treating patients having type 1 diabetes with eflornithine | |
| JP2019065032A (ja) | コルヒチンの徐放性製剤およびその使用方法 |